Breaking News Instant updates and real-time market news.

ELOS

Syneron Medical

07:38
07/17/17
07/17
07:38
07/17/17
07:38

Syneron Medical completes its acquisition and announces management appointments

Syneron Medical announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400M. As a result of the transaction, Syneron Candela is now a privately held company. Syneron Candela's ordinary shares will cease to trade on The Nasdaq Stock Market before the opening of the market today and will be delisted. In conjunction with the closing of the transaction, Geoffrey Crouse has been appointed CEO and a member of the Board of Directors of Syneron Candela. Crouse has successfully led businesses in the life sciences sector spanning capital equipment, diagnostics and tools. Prior to joining Syneron Candela, he served as CEO of Cord Blood Registry from 2012 to 2015, when the company was sold to AMAG Pharmaceuticals. Prior, he served as COO of Immucor, a publicly traded company in the in-vitro diagnostics marketplace, and led Health Economics and Reimbursement Outcomes for Roche Diagnostics. Also joining Syneron Candela's senior executive team are Mike Johnson as CFO, Mary Trout as President, Americas, and Todd Van Horn as Chief Business Officer. Barclays acted as exclusive financial advisor to Syneron Candela. Gross, Kleinhendler

ELOS Syneron Medical

08/08/16
BMUR
08/08/16
NO CHANGE
Target $13
BMUR
Buy
Syneron Medical revenue decline not a trend change, says Brean Capital
Brean Capital noted Syneron Medical missed Q2 revenue estimates slightly, but beat on non-GAAP earnings. The firm believes the revenue miss was more internal management driven rather than a trend change. Brean Capital said given the stock's depressed valuation and the strong desire of management to turn around the company, they would be buyers of the shares. The firm reiterated its Buy rating and $13 price target on Syneron Medical shares.
02/13/17
LEER
02/13/17
NO CHANGE
LEER
ZELTIQ takeover raises M&A chances for other aesthetic players, says Leerink
After Allergan (AGN) announced an agreement to acquire ZELTIQ Aesthetics (ZLTQ) for $2.475B, Leerink analyst Richard Newitter said he thinks the deal increases the takeover prospects for other aesthetic players, particularly those with non-invasive fat offerings. With ZELTIQ off the table, Cynosure (CYNO), Syneron Medical (ELOS) and Cutera (CUTR) could "move into play for another strategic acquirer relatively quickly," Newitter tells investors. The analyst adds that he views Cynosure as "a much higher quality asset" than Syneron, but adds that the latter is "significantly cheaper." On ZELTIQ, he thinks Allergan is "likely the final suitor" given the price it has agreed to pay.
02/16/17
GRIF
02/16/17
NO CHANGE
Target $14
GRIF
Buy
Syneron Medical price target raised to $14 from $10 at Griffen Securities
Griffen Securities analyst Zack Ajzenman raised his price target for Syneron Medical to $14 saying the Q4 results show the company's Emerging Products group continues to "exhibit traction." The stock remains "significantly discounted," Ajzenman tells investors in a post-earnings research note. He reiterates a Buy rating on Syneron.
05/12/17
MAXM
05/12/17
DOWNGRADE
Target $11
MAXM
Hold
Syneron Medical downgraded to Hold from Buy at Maxim
Maxim analyst Anthony Vendetti downgraded Syneron Medical to Hold from Buy after the company announced the end of the "go-shop" period under its merger agreement with Partners. The analyst, who does not expect a higher competing offer, lowered his price target on Syneron to $11 from $12.

TODAY'S FREE FLY STORIES

CMS

CMS Energy

$46.89

0.36 (0.77%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Earnings
CMS Energy reports Q2 EPS 33c, consensus 39c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

HTBK

Heritage Commerce

$13.85

-0.14 (-1.00%)

07:01
07/28/17
07/28
07:01
07/28/17
07:01
Recommendations
Heritage Commerce analyst commentary  »

Heritage Commerce premium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

JPM

JPMorgan

$91.55

-0.38 (-0.41%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
JPMorgan says to be 100% reliant on renewable energy by 2020 »

JPMorgan Chase is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

HRC

Hill-Rom

$79.70

-2.88 (-3.49%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Hill-Rom reports Q3 adj. EPS 91c, consensus 91c »

Reports Q3 revenue $689M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 06

    Aug

  • 10

    Aug

  • 15

    Aug

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax raises FY17 adjusted EPS view to $1.65-$1.75 from $1.60-$1.75 

Consensus $1.73.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

CFX

Colfax

$40.83

-0.12 (-0.29%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Earnings
Colfax reports Q2 adjusted EPS 43c, consensus 43c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

DVAX

Dynavax

$9.25

-1.15 (-11.06%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Hot Stocks
Breaking Hot Stocks news story on Dynavax »

Dynavax trading halted,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 31

    Jul

  • 10

    Aug

EA

Electronic Arts

$117.60

-0.4 (-0.34%)

07:00
07/28/17
07/28
07:00
07/28/17
07:00
Recommendations
Electronic Arts analyst commentary  »

Electronic Arts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

UFS

Domtar

$38.49

0.06 (0.16%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Earnings
Domtar reports Q2 EPS 61c, consensus 55c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$11.83

-0.07 (-0.59%)

06:59
07/28/17
07/28
06:59
07/28/17
06:59
Periodicals
Fiat Chrysler's Maserati to launch electric model after 2019, WSJ reports »

Fiat Chrysler CEO Sergio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLP

Valero Energy Partners

$45.16

-0.57 (-1.25%)

06:57
07/28/17
07/28
06:57
07/28/17
06:57
Earnings
Valero Energy Partners reports Q2 EPS 69c, consensus 75c »

Reports Q2 revenue $110M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

ZBH

Zimmer Biomet

$125.44

-3.26 (-2.53%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Zimmer Biomet rating change  »

Zimmer Biomet downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Aug

JCI

Johnson Controls

$40.14

-3.18 (-7.34%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
Johnson Controls rating change  »

Johnson Controls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 08

    Aug

X

U.S. Steel

$25.00

-1.2 (-4.58%)

06:56
07/28/17
07/28
06:56
07/28/17
06:56
Downgrade
U.S. Steel rating change  »

U.S. Steel downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck reports Q2 KEYTRUDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VC

Visteon

$111.53

1.56 (1.42%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QEP

QEP Resources

$7.93

-1.34 (-14.46%)

06:53
07/28/17
07/28
06:53
07/28/17
06:53
Downgrade
QEP Resources rating change  »

QEP Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

MRK

Merck

$63.69

1.89 (3.06%)

06:52
07/28/17
07/28
06:52
07/28/17
06:52
Hot Stocks
Merck CEO Q2 results driven by 'robust momentum for KEYTRUDA' »

"We continued to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

PLT

Plantronics

$53.65

0.15 (0.28%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Downgrade
Plantronics rating change  »

Plantronics downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

VLKAY

Volkswagen

$31.69

-0.66 (-2.04%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Periodicals
California approves Volkswagen's clean vehicle infrastructure plan, Reuters says »

The California Air…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSH

NuStar GP Holdings

$23.55

0.05 (0.21%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Earnings
Breaking Earnings news story on NuStar GP Holdings »

NuStar GP Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

MRK

Merck

$63.69

1.89 (3.06%)

06:51
07/28/17
07/28
06:51
07/28/17
06:51
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

VFC

VF Corp.

$60.81

-0.06 (-0.10%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Upgrade
VF Corp. rating change  »

VF Corp. upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.69

1.89 (3.06%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Hot Stocks
Breaking Hot Stocks news story on Merck »

Merck sees FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jul

  • 28

    Aug

  • 22

    Sep

SAM

Boston Beer

$135.65

1.7 (1.27%)

06:50
07/28/17
07/28
06:50
07/28/17
06:50
Technical Analysis
Technical View: Boston Beer spikes higher after earnings beat and outlook »

The company reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.